Pretransplant conditioning therapy with i.v. BuCy followed by allogeneic hematopoietic stem cell transplantation (BMT) was investigated in a phase II trial in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We gave i.v. Bu at a dose of 0.8 mg/kg every 6 h ؋ 16 doses, followed by Cy 60 mg/kg daily for 2 days. Twenty-six AML patients (18 males/eight females) were treated, only eight of whom were in CR1. The rest were either refractory to induction chemotherapy (four patients) or in a more advanced stage of their disease (14 patients). In addition, nine patients with MDS (1M/8F) were treated. Their median age was 41 years (range 21-64). Engraftment to у500 neutrophils/l was reached at 14 days (range 10-29 days) post BMT, and the median time of neutropenia was only 11 days (range 4-28 days). The most common regimen-related toxicity was grade 2-3 nausea. In the post-BMT period (including BMT day ؉30), two patients died, one each from pulmonary hemorrhage secondary to CMV pneumonia and hepatic veno-occlusive disease (VOD), for an early treatmentrelated mortality (TRM) of 5.7%. Three patients developed VOD and two of them died. There was no direct regimen-related pulmonary or neurologic toxicity. Overall, the clinical side-effect spectrum was analogous to what would be expected from a high-dose oral Bu-based regimen; there was no unique toxicity experienced with the used solvent system. The disease-free survival in the high-risk subgroup (all patients not in CR1) at 1 and 2 years post transplant was 44% and 31%, respectively. The 13 patients still alive in CR have been followed for a median of 24 months (range 18-32). Pharmacokinetic analysis showed very good interdose reproducibility, and limited interpatient variability in area under the plasma concentration vs time curve, peak concentration, and clearance of Bu after this i.v. formulation. We conclude, that this new i.v. Bu formulation is well tolerated; it has an impressive safety profile, and we suggest that it should be considered as appropriate replacement for oral busulfan in pretrans- 
High-dose oral busulfan (Bu) in combination with cyclophosphamide (Cy) or other cytotoxic agents is often used as an alternative to total body irradiation (TBI)-based therapy in pretransplant conditioning regimens, especially in previously irradiated patients. Bu-based treatment is felt to be convenient and efficacious, although the few available randomized studies have failed to conclusively demonstrate an advantage of Bu-based vs TBI-based treatment. [1] [2] [3] [4] [5] A major shortcoming of oral Bu in high-dose therapy is its very erratic and unpredictable intestinal absorption/bioavailability. This is a problem, since the resulting plasma concentration pattern has been correlated with both toxicity in patients with high/complete drug absorption, [6] [7] [8] [9] and graft rejection/recurrent leukemia in patients who absorb a suboptimal fraction of the delivered dose. 10, 11 To overcome this drawback we developed an intravenous Bu formulation. 12, 13 In a modified phase I dosefinding study we determined that a parenteral Bu dose of 0.8 mg/kg should give similar pharmacokinetic (PK) parameters to those obtained after an oral dose of 1.0 mg/kg BW. We here report the use of this Bu formulation in combination with Cy in 35 patients undergoing allogeneic stem cell transplantation (BMT) for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
Patients and methods
Thirty-five patients with AML or MDS were included in this study (not eligible for a treatment protocol of higher institutional priority). This included patients with AML past first remission (CR, 14 patients), or in first CR but were considered at high risk for recurrent disease (eight patients). It also included those who had failed to achieve complete remission after induction chemotherapy (four patients), and finally nine MDS patients, five of whom had a history of a previous malignancy. Patients were eligible for study treatment if they were between the physiologic ages of 15 and 55 years. They must have normal hepatic function (bilirubin р1.0 mg%, SGPT Ͻ3ϫ upper reference limit) and renal function (creatinine р1.5 mg%), and have a cardiac LVEF у50%, and DLCO у50%, and a matched related allogeneic marrow or stem cell donor available. All patients volunteered a written informed consent in accordance with institutional guidelines.
The i.v. Bu Busulfex (Busulfan) injection (Orphan Medical, Minnetonka, MN, USA) was administered through a central venous catheter at 0.8 mg/kg BW over 2 h every 6 h for 16 doses. The i.v. Bu was diluted in 5% dextrose in water (D5W) or normal saline (NS). This was followed by two daily doses of cyclophosphamide at 60 mg/kg BW, 14 and BMT was performed after a day of rest. Supportive care was provided per each site's institutional guidelines. This included prophylactic treatment with phenytoin during Bu administration, hydration and Mesna during the cyclophosphamide phase of conditioning and immunosuppressive therapy with low-dose methotrexate and either tacrolimus or cyclosporin.
There were 19 males and 16 females with a median age of 41 years (range 21-64). Sixteen of the 35 patients were considered heavily pretreated because they had received a previous therapeutic XRT regimen, у3 chemotherapy regimens or had a previous BMT (three patients). Successful engraftment, overall survival (OS) and (long-term) diseasefree survival (DFS) were the endpoints of the study. Engraftment was recorded as the first day that the absolute neutrophil count (ANC) exceeded 0.5 ϫ 10 9 /l. Failure to engraft would be defined as a failure to reach an ANC у0.5 ϫ 10 9 /l within 100 days after transplantation. Patients who engrafted within the first 100 days after transplantation, but who later developed an ANC Ͻ0.5 ϫ 10 9 /l would be classified as having late graft failure, unless the neutropenia was caused by recurrence of the underlying disease. Relapse was recorded as the day of detection. Survival was recorded as the day of death with the cause of death noted. Patients were monitored for engraftment, relapse and adverse events from BMT day Ϫ7 to day ϩ28, or until discharge from the hospital, and thereafter a minimum of twice weekly until day ϩ28. All patients were monitored for clinical chemistry laboratory parameters twice weekly. Bone marrow examination with cytogenetics were performed at 1 month after BMT or as clinically indicated. Restriction fragment length polymorphism (RFLP) studies were performed to document engraftment. Plasma samples for pharmacokinetic analysis were drawn at doses 1, 9 and 13. Bu plasma concentrations were determined for each time point by a GC-MSD assay. 15 Pharmacokinetic (PK) parameters were determined for each patient's plasma Bu concentration profiles after doses 1, 9 and 13 using the non-compartmental technique (WinNonlin Version 1.1). The peak Bu concentrations (C max ) were observed values after doses 1, 9 and 13. The area under the plasma concentration vs time curve (AUC) was calculated by the linear trapezoidal rule. Apparent plasma clearance (CL) was determined using the dosearea relationship.
Descriptive statistics (mean, median, standard deviation) were calculated for pertinent efficacy parameters: engraftment, relapse, survival, and DFS. The same descriptive statistics were calculated for pharmacokinetic parameters-AUC, T 1/2 and CL.
Results
All patients engrafted at a median of 14 days (range 10-29 days), and the median time of neutropenia was 11 days (range 4-28 days). However, if only the patients who entered the study with a normal absolute neutrophil count (у1500 cells/l) are considered, we observed a delayed onset of neutropenia after completion of the chemotherapy. Thus, the patients would not be neutropenic until day 4-5 post BMT, effectively reducing the median time of chemotherapy-induced neutropenia to 8. Table 1 , with 33 of the 35 patients remaining in or achieving a CR when restaged 1 month after BMT. Three of the eight CR1 patients remain in CR at 21, 24 and 24 months. The higher-risk patient population (18 AML patients not in CR1, and nine MDS patients), demonstrated an OS of 64% and a DFS of 44%, and 31% at 1 and 2 years, respectively (Figure 1 ). The 13 patients who remain in CR have now been followed for a median of 24 months (range 18-32 months). The most common toxicity was grade 2-3 nausea, mostly during the cyclophosphamide phase of the treatment. Among the serious treatment-related events we had two deaths in the first 30 days; one patient died from respiratory failure after pulmonary hemorrhage as a complication of CMV pneumonia, and one patient developed lethal VOD (incidence 2/35, ie 5.7%). Between days BMT ϩ31 and ϩ100, five additional patients died: one patient from VOD; one developed interstitial pneumonitis with ARDS, and then died in a clinical picture of progressive ARDS vs bronchiolitis obliterans (BOOP). This patient had previously received approximately 40 Gy mantle XRT for Hodgkin's disease. Finally, one patient developed hemorrhagic complications after intensified immunosuppressive therapy for graft-versus-host disease, and two patients died of leukemic progression. The overall mortality in the first 100 days post BMT was 7/35 = 20%. Aside from the patient who had pulmonary hemorrhage Summary of outcome assessed 30 days after BMT. At the left is the patient's status at the start of conditioning therapy, at right the outcome assessed on day 30. CR1 = first complete remission; Primary refr. = refractory to primary induction chemotherapy; ϾCR1 = relapse after CR, or more advanced remission; PD = progressive disease; ED = early death, defined as death prior to or on day 30 after BMT. after CMV pneumonia and the patient who had interstitial pneumonitis ARDS vs BOOP, we did not encounter any pulmonary toxicity, and there was no serious neurological toxicity encountered. Hepatic veno-occlusive disease (VOD) was seen in three patients (8.6%): two of them died, one had previously failed an allogeneic BMT after Ctx-TBI. All regimen-related toxicity had been previously described with the use of oral Bu. There was no new and unique toxicity identified that could be associated with the formulation vehicle of dimethylacetamide and PEG-400.
12,13
Acute graft-versus-host disease was encountered in five patients, one of whom died on BMT day ϩ62 of hemorrhagic complications after intensified immunosuppressive therapy.
The plasma PK analysis at doses 1, 9 and 13 revealed an excellent interdose reproducibility of all parameters ( Table 2 ). The mean AUC value after dose 1 was 1130 Ϯ 353 mol-min Ϯs.d., and it was 1169 Ϯ 225 mol-min after dose 9, demonstrating excellent inter-dose reproducibility.
Discussion
Oral Bu is a popular alternative to TBI in high-dose conditioning therapy prior to BMT. Unfortunately, the unpre- Table 2 Pharmacokinetic parameters Bone Marrow Transplantation dictable intestinal Bu absorption yields highly variable inter-and intra-individual plasma concentrations. High plasma Bu concentrations have been correlated with serious hepatic and neurologic toxicity, [6] [7] [8] [9] although not all investigators have been able to confirm these observations. 16 Further, it has been reported that low plasma Bu levels are associated with an increased risk for both graft rejection and disease recurrence post BMT. 10, 11 To circumvent the unpredictable intestinal drug absorption and individual variations in drug metabolism, individualized Bu dosing based on first-dose Bu plasma PK has been advocated. 6, 17 Although intellectually very appealing, such an individualized dosing approach does not take into account that many patients vomit after the first dose, and neither does it consider that some patients have a delayed intestinal drug absorption, resulting in Bu blood levels that are still increasing at the end of the customary 6-h dosing interval.
9,18 Therefore, we developed the present parenteral, pharmaceutically acceptable formulation 12, 13 for use in pretransplant conditioning therapy. Assessed by peripheral blood counts all patients engrafted, and donor-derived hematopoiesis was confirmed in all 25 patients who had RFLP and/or cytogenetic data available at 1 or 3 months post BMT. Our study illustrates that the new formulation is well tolerated and is an effective conditioning therapy for AML and MDS.
The toxicity profile of the new i.v. Bu was analogous to what could be expected with an oral Bu-based conditioning regimen when used in a high-risk patient population (for example see Refs 4, 19) . However, the low overall incidence of serious VOD and absence of serious CNS toxicity in our patients compares favorably with other published studies using oral Bu-based conditioning therapy. 4, 19 In addition, the absence of any toxicity that could be attributed to the used solvent vehicle is encouraging and supports the use of the DMA/PEG400 formulation. The PK analysis showed similar clearance of our i.v. Bu to previously published data obtained with the standard oral preparation (cf.
Ref. 8) . This indicates that the solvent vehicle does not alter human Bu metabolism in the used regimen. The PK parameters' high inter-dose reproducibility was illustrated by the mean values of AUC, C max , and clearance after doses 1, 9 and 13 ( Table 2 ). The lack of solvent system toxicity, the reproducible PK profile, and the DFS of 44% and 31% at 1 and 2 years post transplant, respectively, in this highrisk patient subgroup suggests, that the new i.v. Bu formulation is at least equivalent to the standard tablets. In addition, the i.v. formulation lacks the problems associated with unpredictable, erratic intestinal absorption and possible hepatic first-pass effect experienced with the tablets.
In summary, the good clinical tolerance and reproducible PK data should encourage the use of i.v. Bu in prospective investigations of how to optimize Bu dosing schedules to further improve both treatment safety and long-term DFS.
Our observations suggest that the new i.v. Bu should be further evaluated as replacement for oral Bu in high-dose pretransplant conditioning therapy.
